lg1

LG100754 (UVI 2112) is an insulin sensitizer that functions through RXR. LG100754 is an RXR dimer modulator. LG100754 acts as an RXR: RXR homodimer antagonist, but functions as an agonist towards RXR: PPARα and RXR: PPARγ heterodimers.

LG100268 is a potent, selective, and orally active retinoid X receptor (RXR) agonist that agonizes RXR-α, RXR-β, and RXR-γ at the nanomolar level, selectively exceeding the RAR by three orders of magnitude.LG100268 is capable of inducing transcriptional activation in adipocytes; affecting the RXRs and their chaperone receptor, Foxl2 Dmrt1, to induce flounder masculinization in juvenile flounder; inhibits keratin 17 expression in nigrostriatal epithelial cells; and increases PD-L1 expression in HER2 or triple-negative breast cancer.

LG190155 is a moderately potent VDR agonist. Vitamin D receptor (VDR) agonists are well known for their capacity to control calcium and bone metabolism and to regulate growth and differentiation of many cell types.

LG190119 is a nonsecosteroidal vitamin D receptor modulator. It effectively inhibited LNCaP xenograft tumor growth without increased serum calcium levels or any other apparent side effects. It also inhibits the growth of LNCaP xenograft tumors in athymic

LG157 is a strong inhibitor of the mitotic kinesin-like protein 2 (MKLP2) [1].

LG190178, a vitamin D receptor (VDR) ligand, is a therapeutic agent used for the treatment of psoriasis, osteoporosis, and secondary hyperparathyroidism.

Doxenitoin is an anticonvulsant agent.